Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | TACR2 | P21452 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177199 | 0.89 | TUBB1 (0.51) | TUBB1MMP9MMP8TACR2TACR1 | |
| SCHEMBL14567798 | 0.89 | TUBB1 (0.51) | TUBB1MMP9MMP8TACR2TACR1 | |
| SCHEMBL57330 | 0.89 | TUBB1 (0.51) | TUBB1MMP9MMP8TACR2TACR1 | |
| SCHEMBL22692367 | 0.85 | TUBB1 (0.57) | TUBB1 | |
| SCHEMBL22692378 | 0.85 | TUBB1 (0.57) | TUBB1 | |
| SCHEMBL22692357 | 0.85 | TUBB1 (0.57) | TUBB1 | |
| SCHEMBL15429694 | 0.82 | TUBB1 (0.42) | TUBB1MMP9MMP8TACR2TACR1 | |
| SCHEMBL13682573 | 0.82 | TUBB1 (0.42) | TUBB1MMP9MMP8TACR2TACR1 | |
| SCHEMBL13681885 | 0.82 | TUBB1 (0.42) | TUBB1MMP9MMP8TACR2TACR1 | |
| SCHEMBL14567811 | 0.82 | TUBB1 (0.42) | TUBB1MMP9MMP8TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | TUBB1 176/4885MMP9 3261/4885MMP8 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.